Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726546 | 0.86 | PTGDR2 (0.36) | PTGDR2CA1CA2CA9 | |
| SCHEMBL5757756 | 0.82 | CA1 (0.42) | PTGDR2CA1CA2CA9KLKB1 | |
| SCHEMBL17986394 | 0.82 | CTSL (0.48) | PTGDR2CA1CA2CA9KLKB1 | |
| SCHEMBL1909424 | 0.82 | PTGDR2 (0.44) | PTGDR2CA1CA2CA9KLKB1 | |
| Hydrochloric Acid SCHEMBL29243840 | 0.81 | CA1 (0.41) | PTGDR2CA1CA2CA9KLKB1 | |
| SCHEMBL16880254 | 0.77 | PTGDR2 (0.46) | PTGDR2CA1CA2CA9KLKB1 | |
| SCHEMBL31028753 | 0.76 | PTGDR2 (0.44) | PTGDR2CA1CA2CA9CTSL | |
| SCHEMBL1725785 | 0.76 | PTGDR2 (0.44) | PTGDR2CA1CA2CA9CTSL | |
| SCHEMBL6738209 | 0.73 | PTPN1 (0.42) | PTGDR2 | |
| SCHEMBL16888061 | 0.73 | ALDH1A1 (0.49) | PTGDR2KLKB1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290465-B2 | Substituted isoxazole amine compounds as inhibitors of SCD1 | HOFFMANN-LA ROCHE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN-LA ROCHE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2925408-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086667-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| EP-1562902-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | PTGDR2 266/4885CA1 4595/4885CA2 2787/4885 |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | SCD, CPT1A, SCD5 | PTGDR2 1200/4885CA1 2582/4885CA2 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.